Influenza virus vaccine liposomal - Crucell

Drug Profile

Influenza virus vaccine liposomal - Crucell

Alternative Names: InfectoVac Flu; Inflexal V; Invivac; Isiflu V; Viroflu

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Berna Biotech
  • Developer Crucell
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Market Withdrawal Influenza virus infections

Most Recent Events

  • 18 Oct 2013 Isconova has been acquired by Novavax
  • 06 Sep 2013 Isconova is now called Novavax AB
  • 01 Aug 2013 Crucell completes a phase III trial in Influenza virus infections (prevention; 2013/2014 season influenza vaccine) in Switzerland (NCT01893177)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top